Elocon Ointment

  • Name:

    Elocon Ointment

  • Company:
    info
  • Active Ingredients:

    Mometasone Furoate

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 02/10/17

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 25/6/2019

Click on this link to Download PDF directly

MSD Ireland (Human Health) Limited

MSD Ireland (Human Health) Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Adempas Film Coated Tablets Active Ingredients Riociguat
Medicine Name Arcoxia 30 60 90 120 film-coated tablets Active Ingredients Etoricoxib
Medicine Name Atozet 10mg/10mg, 10mg/20mg, 10mg/40mg and 10mg/80mg film-coated tablets Active Ingredients Atorvastatin calcium trihydrate, ezetimibe
Medicine Name Bridion Active Ingredients Sugammadex sodium
Medicine Name Cancidas 50mg Powder for concentrate for solution for infusion Active Ingredients caspofungin acetate
Medicine Name Cancidas 70mg Powder for concentrate for solution for infusion Active Ingredients caspofungin acetate
Medicine Name Cerazette 75 microgram film-coated tablet Active Ingredients Desogestrel
Medicine Name Cozaar 12.5mg, 50mg & 100mg Film-coated Tablets Active Ingredients Losartan potassium
Medicine Name Cozaar 2.5mg/ml Powder and Solvent for Oral Suspension Active Ingredients Losartan potassium
Medicine Name Cozaar COMP 50 mg/12.5 mg, 100 mg/12.5 mg, 100 mg/25 mg film-coated tablets Active Ingredients Hydrochlorothiazide, Losartan potassium
Medicine Name Cubicin 350mg Powder for Solution for injection or infusion Active Ingredients Daptomycin
Medicine Name Cubicin 500mg powder for solution for injection or infusion Active Ingredients Daptomycin
Medicine Name Delstrigo 100 mg/300 mg/245 mg film-coated tablets Active Ingredients Lamivudine, Tenofovir disoproxil fumarate, Doravirine
Medicine Name Diprosalic Scalp Application Active Ingredients Betamethasone dipropionate, Salicylic Acid
Medicine Name Elocon Cream Active Ingredients Mometasone Furoate
Medicine Name Elocon Ointment Active Ingredients Mometasone Furoate
Medicine Name Elocon Scalp Lotion Active Ingredients Mometasone Furoate
Medicine Name EMEND 125 mg hard capsules Active Ingredients Aprepitant
Medicine Name EMEND 80 mg hard capsules Active Ingredients Aprepitant
Medicine Name EMEND 80mg, 125mg hard Capsules Active Ingredients Aprepitant
Medicine Name Esmeron Active Ingredients Rocuronium Bromide
Medicine Name EZETROL 10 mg Tablets Active Ingredients ezetimibe
Medicine Name FOSAMAX Once Weekly 70 mg Tablets Active Ingredients Alendronate Sodium Trihydrate
Medicine Name FOSAVANCE Active Ingredients Alendronate Sodium Trihydrate, Colecalciferol (Vitamin D3)
Medicine Name GARDASIL Active Ingredients human papillomavirus vaccine
1 - 0 of 84 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 25 June 2019 SmPC

Reasons for updating

  • Improved presentation of SmPC

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Converted the SPC from word format to pdf file format 

 

Updated on 2 October 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 2 October 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 27 September 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The changes include: updates to the SPC in sections 4.4 Special warnings and precautions for use, 4.8 Undesirable effects, 5.1 Pharmacodynamic properties and 10 Date of revision of the text following HPRA approval for a PRAC recommendation for a visual disturbance.

Updated on 27 September 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 19 May 2015 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Addition of information on reporting a side effect.

Updated on 17 April 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 – addition of the warning related to the systemic side effects following topical application of corticosteroids
Section 4.8 – addition of the ‘Reporting side effects’ paragraph at the end of the section
Section 10 – last revision date change to March 2015  

Updated on 22 April 2014 PIL

Reasons for updating

  • Change to MA holder contact details

Updated on 22 April 2014 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

  • Change to Section 7 - Marketing authorisation holder. IE MAH address changed from Pelham House to Red Oak North  
  • Updated on 13 June 2012 PIL

    Reasons for updating

    • Change to, or new use for medicine
    • Change to warnings or special precautions for use

    Updated on 20 February 2012 SmPC

    Reasons for updating

    • Change to section 4.3 - Contraindications
    • Change to section 4.4 - Special warnings and precautions for use
    • Change to section 4.8 - Undesirable effects

    Legal category: Product subject to medical prescription which may be renewed (B)

    Free text change information supplied by the pharmaceutical company

    Amending Section 4.3; 4.4; 4.8

    Updated on 17 February 2012 SmPC

    Reasons for updating

    • Change to section 4.3 - Contraindications
    • Change to section 4.4 - Special warnings and precautions for use
    • Change to section 4.8 - Undesirable effects

    Legal category: Product subject to medical prescription which may be renewed (B)

    Free text change information supplied by the pharmaceutical company

    To Amend Section 4.3; 4.4; 4.8

    Updated on 15 February 2012 SmPC

    Reasons for updating

    • Change to section 4.3 - Contraindications
    • Change to section 4.4 - Special warnings and precautions for use
    • Change to section 4.8 - Undesirable effects

    Legal category: Product subject to medical prescription which may be renewed (B)

    Free text change information supplied by the pharmaceutical company

    To amend sections 4.3; 4.4; 4.8.

    Updated on 17 February 2011 PIL

    Reasons for updating

    • Change to date of revision
    • Change to marketing authorisation holder

    Updated on 17 February 2011 SmPC

    Reasons for updating

    • Change to section 7 - Marketing authorisation holder
    • Change to section 10 - Date of revision of the text

    Legal category: Product subject to medical prescription which may be renewed (B)

    Free text change information supplied by the pharmaceutical company

    • In section 7 of the SPC, the name and address of the marketing authorisation holder has changed to: Merck Sharp & Dohme Ireland (Human Health) Limited, Pelham House, South County Business Park, Leopardstown, Dublin 18, Ireland.
    • In section 8, the Marketing Authorisation Number has changed to: PA 1286/35/2.
    • In section 10, the Date of Revision of the Text has changed to:   26 November 2010
    • All of the above changes are the result of a change of ownership following the integration of Schering-Plough with MSD.

     

    Updated on 26 January 2010 PIL

    Reasons for updating

    • New PIL for medicines.ie

    Updated on 25 November 2009 SmPC

    Reasons for updating

    • Change to section 2 - Qualitative and quantitative composition
    • Change to section 4.4 - Special warnings and precautions for use
    • Change to section 4.8 - Undesirable effects
    • Change to section 10 - Date of revision of the text

    Legal category: Product subject to medical prescription which may be renewed (B)

    Free text change information supplied by the pharmaceutical company

    Ointment

     

    Section 2 – Addition of the following:

     

                Propylene glycol stearate 2.0% w/v (equivalent to 20mg/g)

     

    Section 4.4 – the following sentences have been added at end of section:

     

                ELOCON Ointment contains propylene glycol which may cause skin irritation.

     

    Section 4.8 – The first sentence has been changed

     

    From:

    Local side effects include burning, pruritis, tingling, stinging and signs of skin atrophy.

     

    To:

    Local side effects include pruritis, tingling, stinging, application site reactions, bacterial infections, folliculitis, furunculosis, acneiform eruptions and signs of skin atrophy.  

     

    Additional local side effects reported infrequently when topical dermatological corticosteroids have been used as recommended include: burning, irritation, dryness, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria.

     

    Section 10 – date of revision of text updated from February 2007 to July 2007

    Updated on 15 August 2007 SmPC

    Reasons for updating

    • Change to section 2 - Qualitative and quantitative composition
    • Change to section 6.1 - List of excipients
    • Change to section 6.2 - Incompatibilities
    • Change to section 6.5 - Nature and contents of container
    • Change to section 6.6 - Special precautions for disposal and other handling
    • Change to section 9 - Date of renewal of authorisation
    • Change to section 10 - Date of revision of the text

    Legal category: Product subject to medical prescription which may be renewed (B)

    Free text change information supplied by the pharmaceutical company

    Section 2 changed from:
                     Mometasone Furoate 0.1% w/v
                     For excipients, see section 6.1
     
    To:
                     Mometasone Furoate 0.1% w/v (equivalent to 1.0mg/g)
                     For a full list of excipients, see section 6.1
     
    Section 6.1: list of excipients - white wax changed to white beeswax and white petrolatum changed to white soft paraffin
     
    Section 6.2: changed from None known to Not applicable
     
    Section 6.5: the sentence "Not all pack sizes may be marketed" has been added
     
    Section 6.6: changed from Not applicable to No special requirements
     
    Sections 9 and 10: dates revised

    Updated on 28 May 2003 SmPC

    Reasons for updating

    • New SPC for medicines.ie

    Legal category: Product subject to medical prescription which may be renewed (B)